Jefferies Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $12.7M | Hold |
115,000
| – | – | 0.11% | 149 |
|
|
2022
Q2 | $8.62M | Hold |
115,000
| – | – | 0.07% | 226 |
|
|
2022
Q1 | $8.98M | Sell |
115,000
-34,800
| -23% | -$2.66M | 0.06% | 257 |
|
|
2021
Q4 | $13.5M | Buy |
+149,800
| New | +$12.8M | 0.08% | 212 |
|
|
2021
Q1 | – | Sell |
-30,400
| Closed | -$5.18M | – | 1969 |
|
|
2020
Q4 | $5.18M | Buy |
30,400
+15,500
| +104% | +$2.3M | 0.04% | 397 |
|
|
2020
Q3 | $2.09M | Hold |
14,900
| – | – | 0.02% | 555 |
|
|
2020
Q2 | $2.39K | Hold |
14,900
| – | – | 0.03% | 492 |
|
|
2020
Q1 | $1.46M | Buy |
14,900
+6,700
| +82% | +$766K | 0.02% | 827 |
|
|
2019
Q4 | $1.06M | Sell |
8,200
-35,100
| -81% | -$3.54M | 0.01% | 1432 |
|
|
2019
Q3 | $3.26M | Sell |
43,300
-6,900
| -14% | -$815K | 0.03% | 754 |
|
|
2019
Q2 | $7.63M | Buy |
50,200
+40,200
| +402% | +$4.89M | 0.06% | 300 |
|
|
2019
Q1 | $1.19M | Sell |
10,000
-29,600
| -75% | -$3.81M | 0.01% | 1187 |
|
|
2018
Q4 | $4.32M | Buy |
39,600
+8,000
| +25% | +$1M | 0.04% | 483 |
|
|
2018
Q3 | $5.1M | Sell |
31,600
-20,400
| -39% | -$2.79M | 0.03% | 520 |
|
|
2018
Q2 | $6.87M | Buy |
+52,000
| New | +$4.9M | 0.04% | 391 |
|
|
2018
Q1 | – | Sell |
-2,600
| Closed | -$145K | – | 2684 |
|
|
2017
Q4 | $145K | Hold |
2,600
| – | – | ﹤0.01% | 2285 |
|
|
2017
Q3 | $118K | Buy |
+2,600
| New | +$104K | ﹤0.01% | 2153 |
|
|
2017
Q2 | – | Sell |
-141,900
| Closed | -$4.2M | – | 2548 |
|
|
2017
Q1 | $4.2M | Sell |
141,900
-1,105,800
| -89% | -$34.2M | 0.03% | 567 |
|
|
2016
Q4 | $34.2M | Sell |
1,247,700
-1,219,300
| -49% | -$49M | 0.19% | 76 |
|
|
2016
Q3 | $151M | Sell |
2,467,000
-869,800
| -26% | -$26.3M | 0.78% | 14 |
|
|
2016
Q2 | $63.6M | Buy |
3,336,800
+2,183,100
| +189% | +$40.4M | 0.29% | 42 |
|
|
2016
Q1 | $22.5M | Buy |
1,153,700
+1,122,200
| +3,563% | +$19.6M | 0.13% | 106 |
|
|
2015
Q4 | $1.22M | Sell |
31,500
-18,500
| -37% | -$600K | 0.01% | 1090 |
|
|
2015
Q3 | $1.61M | Buy |
+50,000
| New | +$1.7M | 0.01% | 991 |
|
|
2015
Q1 | – | Sell |
-138,300
| Closed | -$2M | – | 2362 |
|
|
2014
Q4 | $2M | Hold |
138,300
| – | – | 0.01% | 714 |
|
|
2014
Q3 | $2.92M | Sell |
138,300
-363,000
| -72% | -$8.19M | 0.02% | 603 |
|
|
2014
Q2 | $14.9M | Sell |
501,300
-196,000
| -28% | -$6.2M | 0.13% | 142 |
|
|
2014
Q1 | $16.8M | Sell |
697,300
-442,900
| -39% | -$11.3M | 0.16% | 117 |
|
|
2013
Q4 | $23.2M | Buy |
1,140,200
+118,200
| +12% | +$3.51M | 0.15% | 73 |
|
|
2013
Q3 | $48.3M | Buy |
1,022,000
+270,400
| +36% | +$10.4M | 0.47% | 30 |
|
|
2013
Q2 | $28.6M | Buy |
+751,600
| New | +$26.9M | 0.31% | 40 |
|
Other funds holding SRPT
ACA
EC
Jefferies Group's SRPT Position: Q3 2022 in Review
Jefferies Group reduced its Sarepta Therapeutics (SRPT) stake by 33% in Q3 2022, selling an estimated $2.92M and leaving 57,628 shares worth $6.37M. The position accounts for 0.05% of the portfolio, ranked #297.
Jefferies Group first reported a position in SRPT in Q2 2013 and has held it in 31 quarters since. The position peaked at $142M in Q3 2016. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.
- Jefferies Group held 57,628 shares of Sarepta Therapeutics worth $6.37M as of Q3 2022.
- Jefferies Group sold 28,991 Sarepta Therapeutics shares in Q3 2022, an estimated $2.92M.
- Sarepta Therapeutics made up 0.05% of Jefferies Group's portfolio in Q3 2022, its #297 holding.
- Jefferies Group first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 31 quarters since.
- Jefferies Group's Sarepta Therapeutics position peaked at $142M in Q3 2016.
- 375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.